For research use only. Not for therapeutic Use.
Bretazenil (CAT: I004986) is a benzodiazepine derivative that acts as a selective agonist for the benzodiazepine receptor subtype known as the alpha-1 receptor. It exhibits anxiolytic and sedative effects by binding to the GABA-A receptors in the brain, enhancing the inhibitory actions of the neurotransmitter GABA. Bretazenil is known for its relatively high affinity and selectivity for the alpha-1 subunit, which is associated with anxiolytic and sedative effects. It has been investigated for its potential use in the treatment of anxiety disorders and as a safer alternative to other benzodiazepines due to its lower affinity for subtypes associated with adverse effects.
| Catalog Number | I004986 |
| CAS Number | 84379-13-5 |
| Synonyms | Ro 16-6028; Ro 16 6028; Ro16-6028; Ro 166028; Ro 166028; Ro166028; Ro 16-6028/000; Bretazenil;tert-butyl (S)-8-bromo-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo[1,2-a][1,4]diazepine-1-carboxylate |
| Molecular Formula | C19H20BrN3O3 |
| Purity | ≥95% |
| Target | GABA Receptor |
| Solubility | Soluble in DMSO |
| Storage | Desiccate at +4°C |
| InChI | InChI=1S/C19H20BrN3O3/c1-19(2,3)26-18(25)15-16-13-8-5-9-22(13)17(24)14-11(20)6-4-7-12(14)23(16)10-21-15/h4,6-7,10,13H,5,8-9H2,1-3H3/t13-/m0/s1 |
| InChIKey | LWUDDYHYYNNIQI-ZDUSSCGKSA-N |
| SMILES | CC(C)(C)OC(=O)C1=C2C3CCCN3C(=O)C4=C(N2C=N1)C=CC=C4Br |
| Reference | 1: Cole JC, Rodgers RJ. An ethological analysis of the effects of <br> 3: Bronson ME. Tolerance/cross-tolerance to the discriminative stimulus effects <br> |
